Jun 08, 2026
Summary HR+/HER2- breast cancer continues to represent a major target indication for SERDs, with approximately 481,000 cases reported in 2024 in the 7MM. High-profile failures from Sanofi (amcenestrant) and a long list of early-stage candidates such as GDC-029, AZD9496, GDC-0927, ZnC5, LSZ-102, brinale...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Mar 02, 2026
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper